Bayer cancer drug races through FDA approval

Fast track indeed. Only three months after granting accelerated-approval status to Bayer's blockbuster hopeful regorafenib, a treatment for colorectal cancer, FDA gave the drug its final blessing. Bayer will market the drug under the brand name Stivarga, and analysts expect it to peak with at least $1.25 billion in sales. Report